1. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
- Author
-
Morelli, E, Leone, E, Cantafio, M E Gallo, Di Martino, M T, Amodio, N, Biamonte, L, Gullà, A, Foresta, U, Pitari, M R, Botta, C, Rossi, M, Neri, A, Munshi, N C, Anderson, K C, Tagliaferri, P, and Tassone, P
- Subjects
- *
INTERFERON regulatory factors , *MICRORNA , *MULTIPLE myeloma , *MULTIPLE myeloma treatment , *IN vitro studies , *DOWNREGULATION , *PATIENTS , *RNA physiology , *AUTOPHAGY , *ANIMAL experimentation , *APOPTOSIS , *CELL lines , *CELL physiology , *MICE , *ONCOGENES , *PROTEINS , *RESEARCH funding - Abstract
Interferon regulatory factor 4 (IRF4) is an attractive therapeutic target in multiple myeloma (MM). We here report that expression of IRF4 mRNA inversely correlates with microRNA (miR)-125b in MM patients. Moreover, we provide evidence that miR-125b is downregulated in TC2/3 molecular MM subgroups and in established cell lines. Importantly, constitutive expression of miR-125b-5p by lentiviral vectors or transfection with synthetic mimics impaired growth and survival of MM cells and overcame the protective role of bone marrow stromal cells in vitro. Apoptotic and autophagy-associated cell death were triggered in MM cells on miR-125b-5p ectopic expression. Importantly, we found that the anti-MM activity of miR-125b-5p was mediated via direct downregulation of IRF4 and its downstream effector BLIMP-1. Moreover, inhibition of IRF4 translated into downregulation of c-Myc, caspase-10 and cFlip, relevant IRF4-downstream effectors. Finally, in vivo intra-tumor or systemic delivery of formulated miR-125b-5p mimics against human MM xenografts in severe combined immunodeficient/non-obese diabetic mice induced significant anti-tumor activity and prolonged survival. Taken together, our findings provide evidence that miR-125b, differently from other hematologic malignancies, has tumor-suppressor activity in MM. Furthermore, our data provide proof-of-concept that synthetic miR-125b-5p mimics are promising anti-MM agents to be validated in early clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF